Institution
Monash University
Education•Melbourne, Victoria, Australia•
About: Monash University is a education organization based out in Melbourne, Victoria, Australia. It is known for research contribution in the topics: Population & Poison control. The organization has 35920 authors who have published 100681 publications receiving 3027002 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Clinical pathways are associated with reduced in-hospital complications and improved documentation without negatively impacting on length of stay and hospital costs.
Abstract: Background
Clinical pathways are structured multidisciplinary care plans used by health services to detail essential steps in the care of patients with a specific clinical problem. They aim to link evidence to practice and optimise clinical outcomes whilst maximising clinical efficiency.
Objectives
To assess the effect of clinical pathways on professional practice, patient outcomes, length of stay and hospital costs.
Search methods
We searched the Database of Abstracts of Reviews of Effectiveness (DARE), the Effective Practice and Organisation of Care (EPOC) Register, the Cochrane Central Register of Controlled Trials (CENTRAL) and bibliographic databases including MEDLINE, EMBASE, CINAHL, NHS EED and Global Health. We also searched the reference lists of relevant articles and contacted relevant professional organisations.
Selection criteria
Randomised controlled trials, controlled clinical trials, controlled before and after studies and interrupted time series studies comparing stand alone clinical pathways with usual care as well as clinical pathways as part of a multifaceted intervention with usual care.
Data collection and analysis
Two review authors independently screened all titles to assess eligibility and methodological quality. Studies were grouped into those comparing clinical pathways with usual care and those comparing clinical pathways as part of a multifaceted intervention with usual care.
Main results
Twenty-seven studies involving 11,398 participants met the eligibility and study quality criteria for inclusion. Twenty studies compared stand alone clinical pathways with usual care. These studies indicated a reduction in in-hospital complications (odds ratio (OR) 0.58; 95% confidence interval (CI) 0.36 to 0.94) and improved documentation (OR 11.95: 95%CI 4.72 to 30.30). There was no evidence of differences in readmission to hospital or in-hospital mortality. Length of stay was the most commonly employed outcome measure with most studies reporting significant reductions. A decrease in hospital costs/ charges was also observed, ranging from WMD +261 US$ favouring usual care to WMD -4919 US$ favouring clinical pathways (in US$ dollar standardized to the year 2000). Considerable heterogeneity prevented meta-analysis of length of stay and hospital cost results. An assessment of whether lower hospital costs contributed to cost shifting to another health sector was not undertaken.
Seven studies compared clinical pathways as part of a multifaceted intervention with usual care. No evidence of differences were found between intervention and control groups.
Authors' conclusions
Clinical pathways are associated with reduced in-hospital complications and improved documentation without negatively impacting on length of stay and hospital costs.
658 citations
••
Princess Margaret Cancer Centre1, National Institutes of Health2, Monash University3, Merck & Co.4, Institute of Cancer Research5, Structural Genomics Consortium6, Pfizer7, GlaxoSmithKline8, Eli Lilly and Company9, Boehringer Ingelheim10, University of Dundee11, Scripps Research Institute12, Mayo Clinic13, Janssen Pharmaceutica14, Novartis15, University of North Carolina at Chapel Hill16, Harvard University17, Takeda Pharmaceutical Company18, Austrian Academy of Sciences19, Icahn School of Medicine at Mount Sinai20, Broad Institute21, Vertex Pharmaceuticals22, Bayer HealthCare Pharmaceuticals23, European Bioinformatics Institute24, University of Toronto25, University of California, San Francisco26, Karolinska University Hospital27, Medical University of Vienna28, CHDI Foundation29, University of Minnesota30, Simon Fraser University31
TL;DR: A community-driven wiki resource to improve quality and convey current best practice on chemical probes, and to help address shortcomings of poor quality or that are used incorrectly generate misleading results.
Abstract: Chemical probes are powerful reagents with increasing impacts on biomedical research. However, probes of poor quality or that are used incorrectly generate misleading results. To help address these shortcomings, we will create a community-driven wiki resource to improve quality and convey current best practice.
656 citations
••
University of Amsterdam1, Brigham and Women's Hospital2, University of Oslo3, SUNY Downstate Medical Center4, University of Sydney5, University of Manchester6, Queen Mary University of London7, Rosalind Franklin University of Medicine and Science8, Pfizer9, Touro University California10, University of Texas Health Science Center at San Antonio11, Monash University12, University of Dundee13, Cornell University14
TL;DR: Among statin-treated patients, on-treatment levels of LDL-C, non-HDL-C and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non- HDL-C than for LDL-B and apolipoproteins.
Abstract: Context The associations of low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (apoB) levels with the risk of cardiovascular events among patients treated with statin therapy have not been reliably documented. Objective To evaluate the relative strength of the associations of LDL-C, non–HDL-C, and apoB with cardiovascular risk among patients treated with statin therapy. Design Meta-analysis of individual patient data from randomized controlled statin trials in which conventional lipids and apolipoproteins were determined in all study participants at baseline and at 1-year follow-up. Data Sources Relevant trials were identified by a literature search updated through December 31, 2011. Investigators were contacted and individual patient data were requested and obtained for 62 154 patients enrolled in 8 trials published between 1994 and 2008. Data Extraction Hazard ratios (HRs) and corresponding 95% CIs for risk of major cardiovascular events adjusted for established risk factors by 1-SD increase in LDL-C, non–HDL-C, and apoB. Results Among 38 153 patients allocated to statin therapy, 158 fatal myocardial infarctions, 1678 nonfatal myocardial infarctions, 615 fatal events from other coronary artery disease, 2806 hospitalizations for unstable angina, and 1029 fatal or nonfatal strokes occurred during follow-up. The adjusted HRs for major cardiovascular events per 1-SD increase were 1.13 (95% CI, 1.10-1.17) for LDL-C, 1.16 (95% CI, 1.12-1.19) for non–HDL-C, and 1.14 (95% CI, 1.11-1.18) for apoB. These HRs were significantly higher for non–HDL-C than LDL-C (P = .002) and apoB (P = .02). There was no significant difference between apoB and LDL-C (P = .21). Conclusion Among statin-treated patients, on-treatment levels of LDL-C, non–HDL-C, and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non–HDL-C than for LDL-C and apoB.
656 citations
••
Sahlgrenska University Hospital1, National Institutes of Health2, University of Paris3, Children's Hospital Oakland Research Institute4, University of Glasgow5, Aarhus University6, Centro Nacional de Investigaciones Cardiovasculares7, Medical University of Vienna8, University of Amsterdam9, University of California, Los Angeles10, University of Western Ontario11, Monash University12, University of Copenhagen13, Royal Perth Hospital14, University of Western Australia15, French Institute of Health and Medical Research16, Oregon Health & Science University17, University of Cambridge18, University of Bristol19, Trinity College, Dublin20, University of Texas Southwestern Medical Center21, Charité22, Utrecht University23, University of the Witwatersrand24, Imperial College London25, Technische Universität München26, University of Helsinki27, University of Groningen28, Hacettepe University29, University of Milan30, Columbia University31
TL;DR: In this paper, the authors proposed a method to solve the problem of the problem: this paper ] of "uniformity" of the distribution of data points in the data set.
Abstract: Abstract
655 citations
••
TL;DR: The Viewpoint is a call for action on this global problem of low back pain and suggests population shifts are more rapid in low-income and middle-income countries, where adequate resources to address the problem might not exist.
655 citations
Authors
Showing all 36568 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bert Vogelstein | 247 | 757 | 332094 |
Kenneth W. Kinzler | 215 | 640 | 243944 |
David J. Hunter | 213 | 1836 | 207050 |
David R. Williams | 178 | 2034 | 138789 |
Yang Yang | 171 | 2644 | 153049 |
Lei Jiang | 170 | 2244 | 135205 |
Dongyuan Zhao | 160 | 872 | 106451 |
Christopher J. O'Donnell | 159 | 869 | 126278 |
Leif Groop | 158 | 919 | 136056 |
Mark E. Cooper | 158 | 1463 | 124887 |
Theo Vos | 156 | 502 | 186409 |
Mark J. Smyth | 153 | 713 | 88783 |
Rinaldo Bellomo | 147 | 1714 | 120052 |
Detlef Weigel | 142 | 516 | 84670 |
Geoffrey Burnstock | 141 | 1488 | 99525 |